Olumiant Packaging

FDA Approves Eli Lilly’s Drug Olumiant For Alopecia


18 Jun 2022 | 0 | by kjh

2559780login-checkFDA Approves Eli Lilly’s Drug Olumiant For Alopecia

Those who suffer from Alopecia will be happy to know that the Food and Drug Administration has approved a drug called Olumiant.  The drug is officially for Alopecia areata.  Alopecia areata is a disease that happens when the immune system attacks hair follicles and causes hair loss. Hair follicles are the structures in the skin that form hair. While hair can be lost from any part of the body, alopecia areata usually affects the head and face. Hair typically falls out in small, round patches about the size of a quarter, but in some cases, hair loss is more extensive. 

Olumiant comes in oral tablets used to treat patients with the disorder that often produces patchy baldness and affects more than 300,000 people in the US each year, the FDA said. Olumiant is a Janus kinase, or JAK, inhibitor, which blocks the immune system from attacking hair follicles. 

Pfizer and Concert Pharmaceuticals are also nearing approval with similar JAK inhibitors, which are already on the market to treat rheumatoid arthritis and other autoimmune diseases.

For more information visit:


0 0 vote
Article Rating
Inline Feedbacks
View all comments
Would love your thoughts, please comment.x